Clinical Trial Update: A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas [Phase 1]

View source ↗

Summary

A Phase 1 trial is evaluating the safety of REGN5837 in combination with odronextamab for adults with aggressive B-cell non-Hodgkin lymphoma and it is currently…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma

Drugs mentioned

• Odronextamab (odronextamab)
• REGN5837

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: B-cell Non-Hodgkins Lymphoma (B-NHL) | Phase 1 | Status: RECRUITING